David Nierengarten
Stock Analyst at Wedbush
(3.35)
# 900
Out of 4,829 analysts
216
Total ratings
39.88%
Success rate
4.09%
Average return
Main Sectors:
Stocks Rated by David Nierengarten
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NVCR NovoCure | Maintains: Neutral | $29 → $27 | $17.38 | +55.35% | 8 | Apr 16, 2025 | |
| KNSA Kiniksa Pharmaceuticals International, | Reiterates: Outperform | $34 | $26.06 | +30.47% | 3 | Apr 16, 2025 | |
| ARGX argenx SE | Reiterates: Outperform | $715 | $549.27 | +30.17% | 19 | Apr 16, 2025 | |
| BPMC Blueprint Medicines | Reiterates: Outperform | $128 | $97.17 | +31.73% | 4 | Apr 16, 2025 | |
| CATX Perspective Therapeutics | Reiterates: Outperform | $11 | $2.35 | +368.09% | 3 | Mar 27, 2025 | |
| IMNM Immunome | Reiterates: Outperform | $33 | $7.46 | +342.36% | 6 | Mar 20, 2025 | |
| STRO Sutro Biopharma | Downgrades: Neutral | $8 → $2 | $0.87 | +129.49% | 7 | Mar 14, 2025 | |
| FATE Fate Therapeutics | Reiterates: Neutral | $5 | $1.04 | +380.77% | 15 | Mar 6, 2025 | |
| BCAX Bicara Therapeutics | Reiterates: Outperform | $31 | $12.97 | +139.01% | 2 | Feb 12, 2025 | |
| SWTX SpringWorks Therapeutics | Reiterates: Outperform | $77 | $46.26 | +66.45% | 6 | Feb 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 | $19.62 | +103.87% | 13 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $87 → $90 | $37.29 | +141.35% | 3 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $40 → $47 | $30.67 | +53.24% | 7 | Nov 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 | $8.12 | +72.41% | 8 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $2.09 | +139.23% | 7 | Oct 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $15 | $1.15 | +1,204.35% | 6 | Sep 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $99 → $115 | $69.85 | +64.64% | 5 | Sep 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $23 | $3.89 | +491.26% | 3 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $20 | $5.08 | +293.70% | 7 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $40 | $9.54 | +319.29% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $45 | $14.10 | +219.15% | 1 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $10 | $1.27 | +687.40% | 4 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $18 | $2.08 | +765.38% | 1 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $44.24 | +28.84% | 3 | Aug 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $5 | $0.36 | +1,288.89% | 8 | Aug 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $5 | $4.99 | +0.20% | 8 | Jun 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $8 → $2 | $1.13 | +76.99% | 4 | May 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $10 | $4.81 | +107.90% | 3 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $11 | $0.15 | +7,170.32% | 7 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $34 → $36 | $8.33 | +332.17% | 6 | May 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $12 | $1.30 | +823.08% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $57 | $17.41 | +227.40% | 3 | Apr 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $60 → $34 | $3.50 | +860.00% | 1 | Mar 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $2 → $7 | $0.32 | +2,095.05% | 2 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $1,400 → $500 | $3.14 | +15,823.57% | 1 | Dec 8, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Outperform | $33 | $6.67 | +395.12% | 2 | Oct 18, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $105 → $60 | $6.02 | +897.51% | 7 | Jul 26, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $11 → $19 | $5.95 | +219.33% | 3 | Sep 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $71 → $75 | $35.11 | +113.61% | 8 | Feb 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.44 | - | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | n/a | $3.17 | - | 2 | May 11, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.43 | - | 3 | Nov 20, 2017 |
NovoCure
Apr 16, 2025
Maintains: Neutral
Price Target: $29 → $27
Current: $17.38
Upside: +55.35%
Kiniksa Pharmaceuticals International,
Apr 16, 2025
Reiterates: Outperform
Price Target: $34
Current: $26.06
Upside: +30.47%
argenx SE
Apr 16, 2025
Reiterates: Outperform
Price Target: $715
Current: $549.27
Upside: +30.17%
Blueprint Medicines
Apr 16, 2025
Reiterates: Outperform
Price Target: $128
Current: $97.17
Upside: +31.73%
Perspective Therapeutics
Mar 27, 2025
Reiterates: Outperform
Price Target: $11
Current: $2.35
Upside: +368.09%
Immunome
Mar 20, 2025
Reiterates: Outperform
Price Target: $33
Current: $7.46
Upside: +342.36%
Sutro Biopharma
Mar 14, 2025
Downgrades: Neutral
Price Target: $8 → $2
Current: $0.87
Upside: +129.49%
Fate Therapeutics
Mar 6, 2025
Reiterates: Neutral
Price Target: $5
Current: $1.04
Upside: +380.77%
Bicara Therapeutics
Feb 12, 2025
Reiterates: Outperform
Price Target: $31
Current: $12.97
Upside: +139.01%
SpringWorks Therapeutics
Feb 12, 2025
Reiterates: Outperform
Price Target: $77
Current: $46.26
Upside: +66.45%
Feb 7, 2025
Maintains: Outperform
Price Target: $40
Current: $19.62
Upside: +103.87%
Dec 2, 2024
Maintains: Outperform
Price Target: $87 → $90
Current: $37.29
Upside: +141.35%
Nov 25, 2024
Maintains: Outperform
Price Target: $40 → $47
Current: $30.67
Upside: +53.24%
Nov 18, 2024
Reiterates: Neutral
Price Target: $14
Current: $8.12
Upside: +72.41%
Oct 22, 2024
Reiterates: Outperform
Price Target: $5
Current: $2.09
Upside: +139.23%
Sep 30, 2024
Reiterates: Outperform
Price Target: $15
Current: $1.15
Upside: +1,204.35%
Sep 16, 2024
Maintains: Outperform
Price Target: $99 → $115
Current: $69.85
Upside: +64.64%
Sep 10, 2024
Reiterates: Outperform
Price Target: $23
Current: $3.89
Upside: +491.26%
Sep 10, 2024
Reiterates: Outperform
Price Target: $20
Current: $5.08
Upside: +293.70%
Sep 4, 2024
Initiates: Outperform
Price Target: $40
Current: $9.54
Upside: +319.29%
Sep 4, 2024
Initiates: Outperform
Price Target: $45
Current: $14.10
Upside: +219.15%
Aug 13, 2024
Reiterates: Outperform
Price Target: $10
Current: $1.27
Upside: +687.40%
Aug 13, 2024
Initiates: Outperform
Price Target: $18
Current: $2.08
Upside: +765.38%
Aug 9, 2024
Reiterates: Outperform
Price Target: $57
Current: $44.24
Upside: +28.84%
Aug 8, 2024
Reiterates: Outperform
Price Target: $5
Current: $0.36
Upside: +1,288.89%
Jun 27, 2024
Reiterates: Neutral
Price Target: $5
Current: $4.99
Upside: +0.20%
May 29, 2024
Downgrades: Neutral
Price Target: $8 → $2
Current: $1.13
Upside: +76.99%
May 24, 2024
Reiterates: Neutral
Price Target: $10
Current: $4.81
Upside: +107.90%
May 10, 2024
Reiterates: Outperform
Price Target: $11
Current: $0.15
Upside: +7,170.32%
May 10, 2024
Maintains: Outperform
Price Target: $34 → $36
Current: $8.33
Upside: +332.17%
Apr 23, 2024
Reiterates: Outperform
Price Target: $12
Current: $1.30
Upside: +823.08%
Apr 23, 2024
Reiterates: Outperform
Price Target: $57
Current: $17.41
Upside: +227.40%
Mar 19, 2024
Maintains: Neutral
Price Target: $60 → $34
Current: $3.50
Upside: +860.00%
Feb 29, 2024
Upgrades: Outperform
Price Target: $2 → $7
Current: $0.32
Upside: +2,095.05%
Dec 8, 2023
Maintains: Equal-Weight
Price Target: $1,400 → $500
Current: $3.14
Upside: +15,823.57%
Oct 18, 2023
Reiterates: Outperform
Price Target: $33
Current: $6.67
Upside: +395.12%
Jul 26, 2023
Maintains: Neutral
Price Target: $105 → $60
Current: $6.02
Upside: +897.51%
Sep 26, 2022
Maintains: Outperform
Price Target: $11 → $19
Current: $5.95
Upside: +219.33%
Feb 14, 2020
Maintains: Outperform
Price Target: $71 → $75
Current: $35.11
Upside: +113.61%
Dec 3, 2019
Downgrades: Neutral
Price Target: n/a
Current: $1.44
Upside: -
May 11, 2018
Upgrades: Outperform
Price Target: n/a
Current: $3.17
Upside: -
Nov 20, 2017
Downgrades: Neutral
Price Target: n/a
Current: $7.43
Upside: -